Clinical study of the recombinant human brain natriuretic peptide treating intractable heart failure
Han Yan
Qian Xiangyang
Abstract：Objective To investigate the clinical effects of the recombinant human brain natriuretic pep-tide ( rhBNP) on intractable heart failure .Methods Sixty-one patients with intractable heart failure were random-ly divided into two groups:rhBNP group ( 30 patients ) was treated with rhBNP combined with conventional anti-heart failure therapy and the control group (31 patients) was treated with conventional anti-heart failure therapy . Therapeutic efficacy was observed and plasma N-terminal pro-brain natriuretic peptide ( NT-proBNP ) levels were measured;cardiac function was detected by ultrasound before and one week after treatment .Results The total ef-fective rate was 93.3%(28/30) in rhBNP group and 67.7%(21/31) in control group.There were significant differences on NT-proBNP level between rhBNP group treated before and after treatment [ ( 1 918 ±466 ) ng/L vs (590 ±81) ng/L, P <0.01].There were significant differences in the left ventricular end diastolic diameter ( LVDD) and left ventricular ejection fraction ( LVEF) between the two groups before and after treatment:[ rhBNP group LVDD:(68 ±8) mm vs (59 ±7)mm, control group LVDD:(66 ±8)mm vs (61 ±8)mm, rhBNP group LVEF:(34 ±7)%vs (45 ±7)%, control group LVEF:(35 ±7)%vs (40 ±8)%].However, there were no differences between rhBNP group and control group regarding LVDD after treatment (P>0.05).Conclusion The study shows that rhBNP can reduce plasma NT-proBNP level significantly .
Keywords：Heart failureCardiac functionNatriuretic peptidebrain
Publication Date：2014-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 1274-1276 )